Safety and Efficacy of the 2.25-mm Sirolimus-Eluting Bx Velocity Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: the SIRIUS 2.25 Trial
2006
Smaller reference vessel diameter is a recognized determinant of in-stent restenosis. The SIRIUS 2.25 trial was a prospective, nonrandomized study including 100 patients (mean age 63.4 years; 64% men, 40% with diabetes mellitus) assessing the safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in patients with de novo native coronary lesions. Using propensity score matching for gender, diabetes mellitus, left anterior descending artery target vessel, lesion length, and reference vessel diameter, the outcomes were compared with historical control groups (angioplasty and Palmaz-Schatz stent arms from the STRESS/BENESTENT I/II trials and the Bx Velocity bare metal stent arm from the RAVEL and SIRIUS trials having a reference vessel diameter
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
16
References
29
Citations
NaN
KQI